Dogwood Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Dogwood Therapeutics is Greg Duncan, benoemd in Apr2020, heeft een ambtstermijn van 4.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 566.92K, bestaande uit 93.3% salaris en 6.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.17% van de aandelen van het bedrijf, ter waarde $ 6.16K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.6 jaar en 3.9 jaar.

Belangrijke informatie

Greg Duncan

Algemeen directeur

US$566.9k

Totale compensatie

Percentage CEO-salaris	93.3%
Dienstverband CEO	4.6yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	4.6yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jun 25

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Mar 09

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Nov 02

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jul 19

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Jun 04

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Mar 31

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Feb 01

Virios Therapeutics prices IPO at $10

Dec 17

Analyse CEO-vergoeding

Hoe is Greg Duncan's beloning veranderd ten opzichte van Dogwood Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$6m
Jun 30 2024	n/a	n/a	-US$5m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$567k	US$529k	-US$5m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$937k	US$529k	-US$12m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$16m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$1m	US$513k	-US$16m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$4m	US$375k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 566.92K ) Greg } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Greg is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Greg Duncan (59 yo)

4.6yrs

Tenure

US$566,923

Compensatie

Mr. Gregory Duncan, also known as Greg, serves as Chief Executive Officer at Dogwood Therapeutics, Inc. (formerly known as Virios Therapeutics, Inc.), (formerly Virios Therapeutics, LLC) since April 01, 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gregory Duncan	Chairman & CEO	4.6yrs	US$566.92k	0.17% $ 6.2k
William Pridgen	Founder & Member of Scientific Advisory Board	12.8yrs	US$42.56k	2.29% $ 81.6k
Angela Walsh	Chief Financial Officer	less than a year	US$282.64k	0.0090% $ 321.7
R. Gendreau	Chief Medical Officer	12.8yrs	US$364.94k	0% $ 0
Ralph Grosswald	Senior Vice President of Operations	4.6yrs	US$425.03k	geen gegevens
Carol Duffy	Chief Scientific Advisor	no data	geen gegevens	geen gegevens

4.6yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DWTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gregory Duncan	Chairman & CEO	6.8yrs	US$566.92k	0.17% $ 6.2k
William Pridgen	Founder & Member of Scientific Advisory Board	less than a year	US$42.56k	2.29% $ 81.6k
John Thomas	Independent Director	3.9yrs	US$57.56k	0.0030% $ 107.1
Ying Choi Yu	Director	less than a year	geen gegevens	geen gegevens
Richard Whitley	Member of Scientific Advisory Board & Independent Director	3.9yrs	US$55.56k	0.0021% $ 75.0
David Keefer	Independent Director	6.8yrs	US$64.06k	0.038% $ 1.4k
Abel De La Rosa	Independent Director	3.9yrs	US$55.06k	0.012% $ 428.8
Michael Camilleri	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Daniel Clauw	Chair of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lesley Arnold	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dedra Buchwald	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Joel Baines	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DWTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Dogwood Therapeutics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Virios Therapeutics, Inc. Appoints Angela Walsh as Chief Financial Officer

Virios Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

High number of new directors

Founder & Director recently bought US$59k worth of stock

High number of new directors

Recent updates

Dogwood Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Listing Rule 5550(b)(1)

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

New major risk - Revenue and earnings growth

Dogwood Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 92% to US$83.33

Virios Therapeutics, Inc. Appoints Angela Walsh as Chief Financial Officer

Virios Therapeutics, Inc. (NasdaqCM:VIRI) acquired Pharmagesic (Holdings) Inc. from Sealbond Limited.

New major risk - Financial position

Virios Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Virios Therapeutics, Inc. Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

New major risk - Revenue and earnings growth

Nasdaq Grants Exception Till October 28 to Virios Therapeutics to Regain Compliance with Minimum Bid Price Requirement

Virios Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

New major risk - Shareholder dilution

Virios Therapeutics, Inc. has filed a Follow-on Equity Offering.

Virios Therapeutics, Inc. Receives Another Letter from Nasdaq

Virios Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Virios Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

New major risk - Revenue and earnings growth

Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid

New major risk - Market cap size

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Insufficient new directors

New major risk - Financial position

Virios Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Virios Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New major risk - Market cap size

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia

Virios Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

Virios Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Price target decreased to US$2.00

High number of new directors

Virios Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Virios Therapeutics Receives Letter Regarding Bid Price Requirement from the Listing Qualifications Department of the Nasdaq

Virios Therapeutics, Inc. Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Virios Therapeutics slides 11% postmarket on proposed stock offering

Virios Therapeutics, Inc. Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07

Virios Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Value Index

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Founder & Director recently bought US$59k worth of stock

Virios Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new directors

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics Inc. Withdraws its Application for Investigational New Drug (IND 157311)

Virios Therapeutics, Inc. Achieves over 50% Enrollment Milestone in Its Phase 2B Clinical Trial for Fibromyalgia

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Virios Therapeutics Receives New Patent for Antiviral Inhibitor Combination

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Growth Index

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Virios Therapeutics, LLC to Report Q4, 2020 Results on Mar 18, 2021

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Virios Therapeutics, LLC has completed an IPO in the amount of $30 million.

Virios Therapeutics prices IPO at $10

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam